Becton Dickinson EBIT Margin 2010-2023 | BDX
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Becton Dickinson (BDX) over the last 10 years. The current EBIT profit margin for Becton Dickinson as of December 31, 2023 is .
| Becton Dickinson EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$19.49B |
$1.96B |
10.07% |
| 2023-09-30 |
$19.37B |
$2.11B |
10.90% |
| 2023-06-30 |
$19.05B |
$2.25B |
11.81% |
| 2023-03-31 |
$18.81B |
$2.24B |
11.90% |
| 2022-12-31 |
$18.74B |
$2.18B |
11.62% |
| 2022-09-30 |
$18.87B |
$2.28B |
12.10% |
| 2022-06-30 |
$18.41B |
$1.88B |
10.20% |
| 2022-03-31 |
$18.38B |
$1.83B |
9.97% |
| 2021-12-31 |
$18.53B |
$1.70B |
9.17% |
| 2021-09-30 |
$19.13B |
$2.25B |
11.77% |
| 2021-06-30 |
$18.57B |
$1.85B |
9.96% |
| 2021-03-31 |
$17.82B |
$1.72B |
9.64% |
| 2020-12-31 |
$17.16B |
$1.65B |
9.63% |
| 2020-09-30 |
$16.07B |
$0.91B |
5.67% |
| 2020-06-30 |
$16.92B |
$1.34B |
7.93% |
| 2020-03-31 |
$17.41B |
$1.61B |
9.23% |
| 2019-12-31 |
$17.36B |
$1.38B |
7.92% |
| 2019-09-30 |
$17.29B |
$1.76B |
10.18% |
| 2019-06-30 |
$17.11B |
$2.22B |
13.00% |
| 2019-03-31 |
$17.04B |
$2.11B |
12.38% |
| 2018-12-31 |
$17.06B |
$2.16B |
12.66% |
| 2018-09-30 |
$15.98B |
$1.51B |
9.44% |
| 2018-06-30 |
$14.75B |
$1.42B |
9.66% |
| 2018-03-31 |
$13.50B |
$0.69B |
5.10% |
| 2017-12-31 |
$12.25B |
$0.95B |
7.73% |
| 2017-09-30 |
$12.09B |
$1.52B |
12.59% |
| 2017-06-30 |
$12.16B |
$1.13B |
9.28% |
| 2017-03-31 |
$12.32B |
$1.87B |
15.16% |
| 2016-12-31 |
$12.42B |
$1.89B |
15.20% |
| 2016-09-30 |
$12.48B |
$1.43B |
11.46% |
| 2016-06-30 |
$12.31B |
$1.63B |
13.22% |
| 2016-03-31 |
$12.23B |
$1.25B |
10.21% |
| 2015-12-31 |
$11.22B |
$1.08B |
9.60% |
| 2015-09-30 |
$10.28B |
$1.07B |
10.45% |
| 2015-06-30 |
$9.42B |
$1.18B |
12.52% |
| 2015-03-31 |
$8.46B |
$1.49B |
17.60% |
| 2014-12-31 |
$8.48B |
$1.58B |
18.59% |
| 2014-09-30 |
$8.45B |
$1.61B |
19.01% |
| 2014-06-30 |
$8.35B |
$1.28B |
15.36% |
| 2014-03-31 |
$8.24B |
$1.24B |
15.06% |
| 2013-12-31 |
$8.17B |
$1.24B |
15.19% |
| 2013-09-30 |
$8.05B |
$1.26B |
15.58% |
| 2013-06-30 |
$7.92B |
$1.57B |
19.79% |
| 2013-03-31 |
$7.85B |
$1.61B |
20.53% |
| 2012-12-31 |
$7.78B |
$1.61B |
20.74% |
| 2012-09-30 |
$7.71B |
$1.56B |
20.21% |
| 2012-06-30 |
$7.61B |
$1.53B |
20.14% |
| 2012-03-31 |
$7.58B |
$1.53B |
20.20% |
| 2011-12-31 |
$7.57B |
$1.59B |
20.97% |
| 2011-09-30 |
$7.58B |
$1.66B |
21.94% |
| 2011-06-30 |
$7.34B |
$1.62B |
22.01% |
| 2011-03-31 |
$7.22B |
$1.59B |
22.05% |
| 2010-12-31 |
$7.10B |
$1.57B |
22.07% |
| 2010-09-30 |
$7.12B |
$1.58B |
22.22% |
| 2010-06-30 |
$7.22B |
$1.65B |
22.79% |
| 2010-03-31 |
$7.21B |
$1.66B |
22.95% |
| 2009-12-31 |
$7.14B |
$1.60B |
22.44% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.086B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
